Key result
Plasma MR-proANP predicts arrhythmic death in patients with ischemic cardiomyopathy and HFrEF.
Why the study?
Do plasma levels of MR-proANP predict arrhythmic death in patients with HFrEF and ischemic cardiomyopathy?
Do plasma levels of MR-proANP predict arrhythmic death in patients with HFrEF and ischemic cardiomyopathy?
Plasma levels of MR-proANP may serve as a useful biomarker for risk stratification of arrhythmic death in patients with ischemic cardiomyopathy and HFrEF.
MR-proANP may aid arrhythmic risk stratification in ICM-HFrEF; leaves open whether it improves outcomes over existing models.
: Patients with HFrEF had elevated levels of CT-ET1, MR-proANP and MR-proADM. Plasma levels of MR-proANP are useful as predictor for arrhythmic death in patients with ICM.
No takes yet. Share an insight, caveat, or question.
Burger et al. (2021) studied this question. Plasma levels of MR-proANP serve as a useful predictor for arrhythmic death in patients with ischemic cardiomyopathy and heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: